The stock of Champions Oncology Inc (NASDAQ:CSBR) is a huge mover today! About 1.83 million shares traded hands or 2408.81% up from the average. Champions Oncology Inc (NASDAQ:CSBR) has declined 51.03% since April 27, 2016 and is downtrending. It has underperformed by 56.25% the S&P500.
The move comes after 7 months positive chart setup for the $25.71M company. It was reported on Nov, 30 by Barchart.com. We have $2.52 PT which if reached, will make NASDAQ:CSBR worth $2.06M more.
Analysts await Champions Oncology Inc (NASDAQ:CSBR) to report earnings on December, 12.
According to Zacks Investment Research, “Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company’s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments. This technology can evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents. Champions Oncology, Inc. is based in Baltimore, Maryland.”
More notable recent Champions Oncology Inc (NASDAQ:CSBR) news were published by: Prnewswire.com which released: “Champions Oncology Signs $2 million Contract” on November 17, 2016, also Prnewswire.com with their article: “Champions Oncology Beats Revenue Guidance for Quarter; Reaffirms Full Year …” published on September 09, 2016, Prnewswire.com published: “Champions Oncology Announces Initiation of Prospective Correlative Trial in …” on January 21, 2016. More interesting news about Champions Oncology Inc (NASDAQ:CSBR) were released by: Prnewswire.com and their article: “Champions Oncology Announces Revenue Up 26%, Projects 43% – 60% Growth For …” published on July 28, 2016 as well as Prnewswire.com‘s news article titled: “Champions Oncology Announces Reverse Stock Split in Preparation for Uplisting …” with publication date: August 12, 2015.
CSBR Company Profile
Champions Oncology, Inc., incorporated on June 4, 1985, is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Firm has two business divisions: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The Company’s POS business provides physicians and patients information to help guide the development of personalized treatment plans. The Company’s TOS business provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The Company’s TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from individual patients that it has preserved for future implantation in mice, along with the patient data and molecular information associated with these tumors, are referred to as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company’s TumorBank. As of April 30, 2016, the Company has approximately 800 PDX Models in its TumorBank. It implants tumors in mice to provide pharmaceutical and biotechnology companies the opportunity to test oncology compounds on multiple tumors to test efficacy and simulate the results of human clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.